The ICD in Heart Failure — Time for a Rethink?

摘要: In a number of primary-prevention trials, implantable cardioverter–defibrillators (ICDs) have been shown to reduce the risk premature death among patients with left ventricular systolic dysfunction after myocardial infarction and heart failure reduced ejection fraction.1 The evidence benefit is less robust for who do not coronary artery disease; single largest trial, involving 458 such patients, did show significant reduction in mortality association ICD therapy.2 As result, current guideline recommendations are based on meta-analysis small trials nonischemic cardiomyopathy, . . .